CL2021002521A1 - Compuestos heteocíclicos y sus usos. - Google Patents

Compuestos heteocíclicos y sus usos.

Info

Publication number
CL2021002521A1
CL2021002521A1 CL2021002521A CL2021002521A CL2021002521A1 CL 2021002521 A1 CL2021002521 A1 CL 2021002521A1 CL 2021002521 A CL2021002521 A CL 2021002521A CL 2021002521 A CL2021002521 A CL 2021002521A CL 2021002521 A1 CL2021002521 A1 CL 2021002521A1
Authority
CL
Chile
Prior art keywords
compounds
heteocyclic
find
oncology
diseases
Prior art date
Application number
CL2021002521A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Jayakanth Kankanala
Brahmam Pujala
Sanjeev Soni
Puja Jaiswal
Deepak Palve
Varun Kumar
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of CL2021002521A1 publication Critical patent/CL2021002521A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos heterocíclicos como inhibidores de Wee1. Los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades y pueden encontrar un uso particular en oncología.
CL2021002521A 2019-04-09 2021-09-28 Compuestos heteocíclicos y sus usos. CL2021002521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962831665P 2019-04-09 2019-04-09

Publications (1)

Publication Number Publication Date
CL2021002521A1 true CL2021002521A1 (es) 2022-04-29

Family

ID=72748693

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002521A CL2021002521A1 (es) 2019-04-09 2021-09-28 Compuestos heteocíclicos y sus usos.

Country Status (14)

Country Link
US (2) US11332473B2 (es)
EP (1) EP3952877A4 (es)
JP (1) JP2022526831A (es)
KR (1) KR20210150476A (es)
CN (1) CN113939296A (es)
AU (1) AU2020271837A1 (es)
BR (1) BR112021019703A2 (es)
CA (1) CA3136492A1 (es)
CL (1) CL2021002521A1 (es)
EA (1) EA202192746A1 (es)
IL (1) IL287026A (es)
MX (1) MX2021012418A (es)
SG (1) SG11202110615TA (es)
WO (1) WO2020210375A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2023280180A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
CN117751122A (zh) * 2021-08-11 2024-03-22 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN117940430A (zh) * 2021-09-22 2024-04-26 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473295B1 (en) 2002-01-18 2009-04-01 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
ES2341545T3 (es) 2003-06-06 2010-06-22 Arexis Ab Uso de compuestos heterociclicos condensados como inhibidores de scce para el tratamiento de enfermedades de la piel.
WO2006039212A2 (en) 2004-09-29 2006-04-13 Portola Pharmaceuticals, Inc. Substituted 2h-1,3-benzoxazin-4(3h)-ones
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
EP2168966B1 (en) 2007-06-15 2016-09-28 Msd K.K. Bicycloaniline derivative
AU2008315048A1 (en) 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CA2745959A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
DK2477628T3 (en) 2009-09-15 2014-11-24 Merck Sharp & Dohme Preparation of crystalline hemihydratformer of dihydropyrazolopyrimidinon
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
WO2013059485A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
JP6692423B2 (ja) 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
KR102030886B1 (ko) 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2017359844B2 (en) 2016-11-16 2021-09-30 Impact Therapeutics (Shanghai), Inc 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound
ES2902050T3 (es) 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
EP3604306B1 (en) * 2017-03-23 2022-10-26 Shanghai de Novo Pharmatech Co., Ltd. Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
CN110914277B (zh) 2017-07-10 2022-08-09 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
SG11202000789WA (en) * 2017-08-01 2020-02-27 Recurium Ip Holdings Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
WO2019096322A1 (zh) 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) 2018-01-05 2023-05-02 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) * 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
AU2019227823A1 (en) 2018-02-28 2020-08-06 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
EP3762385A4 (en) * 2018-03-09 2021-11-24 Recurium IP Holdings, LLC SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDINE-3-ONE
WO2020210380A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210377A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210381A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220168313A1 (en) 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
BR112021019703A2 (pt) 2021-12-14
WO2020210375A1 (en) 2020-10-15
US20200325142A1 (en) 2020-10-15
US11332473B2 (en) 2022-05-17
AU2020271837A1 (en) 2021-11-18
MX2021012418A (es) 2021-11-12
EP3952877A4 (en) 2022-12-14
JP2022526831A (ja) 2022-05-26
EA202192746A1 (ru) 2021-12-29
CA3136492A1 (en) 2020-10-15
EP3952877A1 (en) 2022-02-16
CN113939296A (zh) 2022-01-14
SG11202110615TA (en) 2021-10-28
US20230118115A1 (en) 2023-04-20
IL287026A (en) 2021-12-01
KR20210150476A (ko) 2021-12-10

Similar Documents

Publication Publication Date Title
CL2022001671A1 (es) Inhibidores de sos1
CL2021002521A1 (es) Compuestos heteocíclicos y sus usos.
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
CL2019001481A1 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos.
UY36713A (es) Triazoles para el tratamiento de enfermedades desmielinizantes
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
UY36749A (es) Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
UY37559A (es) Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
CL2019003397A1 (es) Inhibidores pirazólicos de magl.
ECSP21026485A (es) Piridazinonas y sus métodos de uso